Glypican-3 (GPC3)

Product List

At Creative Biolabs, we are committed to developing groundbreaking anti-GPC3 CAR-T therapies. Whether you are interested in our off-the-shelf products or require customized services, our solutions will support your journey toward successful CAR-T therapy development.

Background

Glypican 3 (GPC3), also known as DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB, SGBS, SGBS1, is encoded by the GPC3 gene that belongs to the member of the glypican family. This protein is highly expressed in embryonal tissues such as the developing intestine and the mesoderm-derived tissue, and its expression is downregulated in most adult tissue. GPC3 is able not only to bind more than one growth factor, but also to functionally affect the signaling of different growth factors. GPC3 is related to hepatocellular carcinoma, Wilm's tumor, colorectal malignancies, neuroblastoma, medullary cell carcinoma, mesothelioma, ovarian cancer, and breast cancer. CAR-T cell therapy targeting GPC3 shows promise in inhibiting cancer cell proliferation and may offer a new treatment option for patients with various cancers.

Associated Diseases

GPC3-positive tumors

Breast cancer

Ovarian cancer

Neuroblastoma

Hepatoblastoma

Nephroblastoma

Anti-GPC3 CAR-T Services

Anti-GPC3 CAR-T In Vitro Assays

Anti-GPC3 CAR-T Expression Test

The GPC3 protein products offered by Creative Biolabs serve as valuable tools for the quantification of anti-GPC3 CAR-T cells. Furthermore, the combination of flow cytometry, western blotting, and qPCR provides a comprehensive analysis of anti-GPC3 CAR-T expression.

Fig.1 Detection of CAR expression by western blot and flow cytometry.¹

Anti-GPC3 CAR-T Cytokine Release Test

Creative Biolabs provides GPC3 CAR-T cytokine release tests for evaluating the release of various cytokines. This assay measures the level of specific cytokines released by the CAR-T cells as an indicator of their immune response, ultimately contributing to the development of more effective and safer CAR-T treatments.

Fig.2 The release of cytokines in the co-cultured supernatants was tested by cytometric bead array assays.¹

Anti-GPC3 CAR-T In Vitro Cytotoxicity Assay

Creative Biolabs provides different assays to assess the cytotoxicity of GPC3 CAR-T cells such as Cr-51 release assay, LDH release assay, and flow cytometry-based cytotoxicity assay.

Fig.3 The cytolytic effector function of anti-GPC3 CAR-T against human HCC cell lines PLC/PRF/5 or SK-Hep-1.¹

Anti-GPC3 CAR-T In Vivo Assays

Anti-GPC3 CAR-T Cell Therapy Animal Models

Creative Biolabs provides various in vivo assays to help researchers understand the behavior and potential of anti-GYPA CAR-T cells. By employing various mouse models, such as xenograft models and syngeneic models, we can analyze the antitumor activity of anti-GYPA CAR-T cells and assess their potential for clinical applications.

Efficacy Test of Anti-GPC3 CAR-T

In vivo efficacy tests are crucial for evaluating the efficacy of GPC3 CAR-T cell therapy and guiding its clinical development. We provide in vivo GPC3 CAR-T assay services for monitoring the efficacy of CAR-T cell therapy.

Fig.4 Antitumor activity of GPC3 CAR-T in PLC/PRF/5 tumor-bearing mice. (A) The persistence of T cells in peripheral blood; (B)Tumor growth.¹

Toxicity Evaluation Anti-GPC3 CAR-T

In addition to evaluating the therapeutic efficacy of anti-GPC3 CAR T cells, we also assess the safety and potential side effects of the therapy. We provide various CAR-T toxicity study services including in vivo cytokine release analysis, on/off-target toxicologic analysis, and tumorigenicity analysis.

Fig.5 In vivo evaluation of the antitumor activity of GPC3 CAR-T in a xenograft mouse model.¹

Reference

1. Sun, Yansha, et al. "Chimeric anti-GPC3 sFv-CD3ε receptor-modified T cells with IL7 co-expression for the treatment of solid tumors." Molecular Therapy-Oncolytics 25 (2022): 160-173.